Abstract: Compounds and methods for protein kinase modulation for cancer treatment are disclosed. The compounds and methods disclosed are based on reduced isoalpha acids, commonly found in hops.
Type:
Application
Filed:
June 20, 2007
Publication date:
January 31, 2008
Applicant:
Metaproteomics, LLC
Inventors:
Matthew Tripp, John Babish, Jeffrey Bland, Veera Konda, Amy Hall, Linda Pacioretty, Anu Desai
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Grant
Filed:
October 20, 2003
Date of Patent:
September 18, 2007
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Application
Filed:
March 29, 2007
Publication date:
August 9, 2007
Applicant:
Metaproteomics, LLC
Inventors:
Matthew Tripp, John Babish, Jeffrey Bland, Gary Darland, Robert Lerman, Daniel Lukaczer, DeAnn Liska, Terrence Howell
Abstract: A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.
Abstract: Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.
Type:
Application
Filed:
January 4, 2007
Publication date:
July 19, 2007
Applicant:
Metaproteomics, LLC
Inventors:
Matthew Tripp, Jeffrey Bland, Robert Lerman, Amy Hall, Veera Konda, Anu Desai
Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species or a beta-acid species or derivatives thereof. The composition provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.
Type:
Application
Filed:
February 2, 2007
Publication date:
June 21, 2007
Applicant:
Metaproteomics, LLC
Inventors:
John Babish, Terrence Howell, Linda Pacioretty
Abstract: A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.
Abstract: A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises comprising an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the group consisting of alpha acids, beta acids, essential oils, fats and waxes, with the proviso that component I and II are not the same compound. The composition provides specific inhibition of cyclooxygenase-2 with little or no effect on cyclooxygenase-1.
Abstract: Compositions comprising an effective amount of a curcuminoid species and an effective amount of a diterpene lactone species, a triterpene species or derivatives thereof that have a synergistic effect on specific inhibition of inducible COX-2 activity and have minimal effect on COX-1 activity are disclosed. Methods of using the compositions for providing synergistic anti-inflammatory effects are also disclosed.
Type:
Grant
Filed:
July 16, 2002
Date of Patent:
December 27, 2005
Assignee:
Metaproteomics, LLC
Inventors:
John G. Babish, Terrence Howell, Linda Pacioretty
Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component of a sesquiterpene lactone species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.
Type:
Grant
Filed:
July 31, 2001
Date of Patent:
June 21, 2005
Assignee:
Metaproteomics, LLC
Inventors:
John G. Babish, Terrence Howell, Linda Pacioretty
Abstract: An orally administered, novel dietary supplement or therapeutic composition capable of insulin-like activity in animals, preferably humans, is provided. Contained in the composition are therapeutically effective amounts of vanadyl sulfate, alpha-lipoic acid, taurine, and chromium carnitine. The composition is preferably orally administered on a daily basis for at least about 4 weeks and can be used by normal, healthy individuals as well as diabetics.
Abstract: A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a diterpene triepoxide lactone species and an effective amount of a second component selected from the group consisting of a diterpene lactone species and a triterpene species or derivatives thereof, and provides synergistic anti-inflammatory effects in response to physical or chemical injury or abnormal immune stimulation due to a biological agent or unknown etiology.
Type:
Grant
Filed:
August 1, 2001
Date of Patent:
October 7, 2003
Assignee:
MetaProteomics, LLC
Inventors:
John G. Babish, Terrence Howell, Linda Pacioretty
Abstract: A composition and method for minimizing the absorption of triglycerides and fats in the gastrointestinal tract is described. The composition comprises psyllium and chitosan in a ratio range of 2:1 to 11:1 by weight, preferably 2:1 to 9:1, and most preferably 2:1 to 4:1 to provide a synergistic fat-binding effect.